Seladelpar in patients with primary biliary cholangitis: Need for a closer look!

Reply to: “Seladelpar in patients with primary biliary cholangitis: Need for a closer look!”

“…Mishra and Singh for their interest in our paper 1 in which seladelpar, a potent and selective PPARd agonist, demonstrated dose-dependent improvements in markers of cholestasis and inflammation 1 and would like to clarify the 4 issues that they raised. 2 First, we agree that non-alcoholic fatty liver disease (NAFLD) is a common condition in adults which is likely to be present in a subset of individuals with PBC 3,4 and that a BMI >25 has been associated with steatosis or advanced fibrosis in PBC, 3 but we would also point out that this is not diagnostic of NAFLD and that BMI is only weakly correlated (0.46) with histological steatosis. 4 Teasing out a secondary benefit of seladelpar in patients with PBC and NAFLD would require more than simply monitoring liver stiffness and controlled-attenuation parameter values as suggested.…”